Reuters logo
BRIEF-Regeneron, Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma
2017年9月11日 / 凌晨5点19分 / 9 天前

BRIEF-Regeneron, Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma

Sept 11 (Reuters) - Regeneron Pharmaceuticals Inc

* Regeneron and Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma

* Regeneron and Sanofi announce positive Dupilumab topline results from phase 3 trial in uncontrolled persistent Asthma

* Co, Sanofi announced pivotal phase 3 liberty asthma quest study of met its two primary endpoints

* Results for 200 mg and 300 mg Dupilumab dose groups were generally comparable on both exacerbations and fev

* Cos plan to submit a supplemental biologics license application to U.S. Food and drug administration (FDA) by end of year Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below